Torrent Pharmaceuticals Limited (TORNTPHARM.BO)
INR 3443.4
(1.87%)
INR 3443.4
(1.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 35 Billion INR | 18.39% |
| 2022 | 28.82 Billion INR | 8.77% |
| 2021 | 21.42 Billion INR | 3.82% |
| 2020 | 25.36 Billion INR | 11.33% |
| 2019 | 22.88 Billion INR | 13.06% |
| 2018 | 16.79 Billion INR | 25.75% |
| 2017 | 16.55 Billion INR | 3.5% |
| 2016 | 15.88 Billion INR | -46.72% |
| 2015 | 27.65 Billion INR | 127.36% |
| 2014 | 13.05 Billion INR | 32.44% |
| 2013 | 9.89 Billion INR | 31.13% |
| 2012 | 6.98 Billion INR | 38.95% |
| 2011 | 4.7 Billion INR | 26.57% |
| 2010 | 4.43 Billion INR | -3.31% |
| 2009 | 4.29 Billion INR | 63.9% |
| 2008 | 2.7 Billion INR | 26.34% |
| 2007 | 2.07 Billion INR | 31.28% |
| 2006 | 1.58 Billion INR | 40.16% |
| 2005 | 1.1 Billion INR | 42.48% |
| 2004 | 793.74 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 9.04 Billion INR | 1.53% |
| 2024 Q2 | 9.23 Billion INR | -0.54% |
| 2023 Q2 | 8.51 Billion INR | 3.15% |
| 2023 Q3 | 8.36 Billion INR | -1.76% |
| 2023 Q1 | 8.25 Billion INR | 18.9% |
| 2023 FY | - INR | 18.39% |
| 2023 Q4 | 8.83 Billion INR | 5.62% |
| 2022 Q4 | 6.93 Billion INR | -2.82% |
| 2022 Q3 | 7.14 Billion INR | 2.73% |
| 2022 FY | - INR | 8.77% |
| 2022 Q1 | 7.42 Billion INR | 485.31% |
| 2022 Q2 | 6.95 Billion INR | -6.33% |
| 2021 FY | - INR | 3.82% |
| 2021 Q2 | 7.11 Billion INR | -0.84% |
| 2021 Q1 | 7.17 Billion INR | 15.88% |
| 2021 Q3 | 5.86 Billion INR | -17.58% |
| 2021 Q4 | 1.26 Billion INR | -78.37% |
| 2020 Q3 | 6.15 Billion INR | -4.06% |
| 2020 Q4 | 6.18 Billion INR | 0.61% |
| 2020 FY | - INR | 11.33% |
| 2020 Q2 | 6.41 Billion INR | -3.61% |
| 2020 Q1 | 6.65 Billion INR | 25.21% |
| 2019 Q2 | 5.75 Billion INR | 2.5% |
| 2019 FY | - INR | 13.06% |
| 2019 Q3 | 5.93 Billion INR | 3.13% |
| 2019 Q1 | 5.61 Billion INR | 344.71% |
| 2019 Q4 | 5.31 Billion INR | -10.44% |
| 2018 Q3 | 5.64 Billion INR | 16.77% |
| 2018 Q2 | 4.83 Billion INR | -4.17% |
| 2018 FY | - INR | 25.75% |
| 2018 Q4 | 1.26 Billion INR | -77.63% |
| 2018 Q1 | 5.04 Billion INR | 24.14% |
| 2017 Q4 | 4.06 Billion INR | -6.24% |
| 2017 FY | - INR | 3.5% |
| 2017 Q3 | 4.33 Billion INR | 6.39% |
| 2017 Q2 | 4.07 Billion INR | 1.24% |
| 2017 Q1 | 4.02 Billion INR | 0.75% |
| 2016 Q1 | 4.63 Billion INR | -9.39% |
| 2016 FY | - INR | -46.72% |
| 2016 Q4 | 3.99 Billion INR | 9.02% |
| 2016 Q3 | 3.66 Billion INR | -1.88% |
| 2016 Q2 | 3.73 Billion INR | -19.44% |
| 2015 Q1 | 9.87 Billion INR | 307.09% |
| 2015 Q3 | 6.73 Billion INR | -14.59% |
| 2015 Q4 | 5.11 Billion INR | -24.07% |
| 2015 FY | - INR | 127.36% |
| 2015 Q2 | 7.88 Billion INR | -20.16% |
| 2014 Q4 | 2.42 Billion INR | -20.51% |
| 2014 Q2 | 3.45 Billion INR | -12.44% |
| 2014 FY | - INR | 32.44% |
| 2014 Q1 | 3.94 Billion INR | 17.53% |
| 2014 Q3 | 3.05 Billion INR | -11.59% |
| 2013 Q2 | 1.89 Billion INR | -12.5% |
| 2013 Q4 | 3.35 Billion INR | 48.99% |
| 2013 FY | - INR | 31.13% |
| 2013 Q3 | 2.25 Billion INR | 19.05% |
| 2013 Q1 | 2.16 Billion INR | -3.23% |
| 2012 Q3 | 1.71 Billion INR | 3.01% |
| 2012 Q2 | 1.66 Billion INR | -2.35% |
| 2012 FY | - INR | 38.95% |
| 2012 Q1 | 1.7 Billion INR | 56.52% |
| 2012 Q4 | 2.23 Billion INR | 30.53% |
| 2011 Q3 | 1.33 Billion INR | 0.0% |
| 2011 FY | - INR | 26.57% |
| 2011 Q4 | 1.08 Billion INR | -18.94% |
| 2010 FY | - INR | -3.31% |
| 2009 FY | - INR | 63.9% |
| 2008 FY | - INR | 26.34% |
| 2007 FY | - INR | 31.28% |
| 2006 FY | - INR | 40.16% |
| 2005 FY | - INR | 42.48% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | -178.62% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -5029.341% |
| Sigachi Industries Limited | 883.39 Million INR | -3863.072% |
| Bal Pharma Limited | 345.59 Million INR | -10030.356% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -410.224% |
| Medico Remedies Limited | 150.37 Million INR | -23181.132% |
| Lasa Supergenerics Limited | -65.08 Million INR | 53894.868% |
| Venus Remedies Limited | 711.8 Million INR | -4818.467% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 1038.279% |
| Alpa Laboratories Limited | 86.12 Million INR | -40548.925% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -2138.772% |
| Shilpa Medicare Limited | 2.58 Billion INR | -1252.779% |
| Aarti Drugs Limited | 3.24 Billion INR | -977.676% |
| Lupin Limited | 36.96 Billion INR | 5.301% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 43.339% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 37.73% |
| Windlas Biotech Limited | 781.72 Million INR | -4378.547% |
| Suven Life Sciences Limited | -992.78 Million INR | 3626.431% |
| Eris Lifesciences Limited | 6.98 Billion INR | -401.109% |
| Valiant Laboratories Limited | 12.73 Million INR | -274722.985% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -275.045% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 1340.643% |
| Ipca Laboratories Limited | 13.29 Billion INR | -163.241% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -2267.072% |
| Achyut Healthcare Limited | 524 Thousand INR | -6681140.458% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 74.697% |
| Bajaj HealthCare Limited | 444.51 Million INR | -7775.914% |
| RPG Life Sciences Limited | 1.28 Billion INR | -2631.931% |
| Mankind Pharma Limited | 28.09 Billion INR | -24.613% |
| Laurus Labs Limited | 8 Billion INR | -337.293% |
| Piramal Pharma Limited | 13.05 Billion INR | -168.163% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -8036.568% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -264.051% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | -208.627% |
| Unichem Laboratories Limited | 742.35 Million INR | -4616.026% |
| Sequent Scientific Limited | 549.8 Million INR | -6267.716% |
| Novartis India Limited | 1.26 Billion INR | -2658.19% |
| Wanbury Limited | 985.49 Million INR | -3452.517% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -648.521% |
| Wockhardt Limited | 1.08 Billion INR | -3141.639% |
| Themis Medicare Limited | 562.6 Million INR | -6122.763% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -10723.502% |
| Jubilant Pharmova Limited | 8 Billion INR | -337.293% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -410.131% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 60.34% |
| Divi's Laboratories Limited | 25.43 Billion INR | -37.671% |
| NATCO Pharma Limited | 18.79 Billion INR | -86.271% |
| Gufic Biosciences Limited | 1.48 Billion INR | -2264.744% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -1243.117% |
| Ind-Swift Limited | 1.06 Billion INR | -3187.092% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -1061.415% |
| FDC Limited | 4.4 Billion INR | -695.37% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 42419.557% |
| Granules India Limited | 8.6 Billion INR | -306.909% |
| Medicamen Biotech Limited | 245.66 Million INR | -14151.282% |
| Alkem Laboratories Limited | 24.19 Billion INR | -44.697% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -1385.476% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -267927.102% |
| Brooks Laboratories Limited | 41.72 Million INR | -83799.78% |
| Megasoft Limited | 284.73 Million INR | -12195.711% |
| ZIM Laboratories Limited | 462.09 Million INR | -7476.266% |
| Strides Pharma Science Limited | 3.76 Billion INR | -829.952% |
| Neuland Laboratories Limited | 4.74 Billion INR | -637.328% |
| Morepen Laboratories Limited | 1.72 Billion INR | -1928.426% |
| Hikal Limited | 2.69 Billion INR | -1200.398% |
| Indoco Remedies Limited | 2.64 Billion INR | -1222.591% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -795.522% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -12080.464% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -19911.718% |
| Hester Biosciences Limited | 539.47 Million INR | -6389.647% |